Acute myeloid leukemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• FLT3 36
• TP53 9
• NPM1 26
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• PD-1 4
• PPAR 0
• CXCR4 0
• NRF2 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 7,156 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Updated 4 Nov 2026

  “FDA Clinical Hold”Registry text, quoted unchanged. Source

• Withdrawn

  Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

  NCT07130695· Virginia Commonwealth University· Updated 29 Oct 2026

  “Budgetary constraints”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

  NCT03150004· Medical College of Wisconsin· Updated 21 Oct 2026

  “No longer have funding support to complete the pharmacogenetics component.”Registry text, quoted unchanged. Source

• Suspended

  Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

  NCT03969446· City of Hope Medical Center· Updated 20 Oct 2026

  “Accrual goal Met”Registry text, quoted unchanged. Source

• Suspended

  Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  NCT06454409· City of Hope Medical Center· Updated 20 Oct 2026

  “resources”Registry text, quoted unchanged. Source

• Suspended

  8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

  NCT05263284· City of Hope Medical Center· Updated 20 Oct 2026

  “Safety Issues, status is being updated per PI due to safety issues. Study is now Temporarily Closed to Accrual.”Registry text, quoted unchanged. Source

• Suspended

  Pyronaridine in Acute Myeloid Leukemia (AML)

  NCT05291390· Armaceutica, Inc.· Updated 19 Oct 2026

  “Change of protocol”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Sanofi· Updated 19 Oct 2026

  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns”Registry text, quoted unchanged. Source

• Terminated

  AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

  NCT04062266· M.D. Anderson Cancer Center· Updated 16 Oct 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Suspended

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Updated 15 Oct 2026

  “Timeline Adjustment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

  NCT05436418· National Cancer Institute (NCI)· Source

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  NCT07617363· Washington University School of Medicine· Source

• Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· National Cancer Institute (NCI)· Source

• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· National Cancer Institute (NCI)· Source

• Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Janssen Research & Development, LLC· Source

• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· National Cancer Institute (NCI)· Source

• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· National Cancer Institute (NCI)· Source

• Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  NCT04716452· Keystone Nano, Inc· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 16
• Gene Expression Profiling 84
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 86
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 159
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Personalized Prediction of Venetoclax-Associated Tumor Lysis Syndrome in Acute Myeloid Leukemia Using Drug Exposure, Genetic Polymorphisms, and Clinical-Laboratory Characteristics.

  Drug Des Devel Ther, Oct 2026

• Computational deconvolution of drug sensitivity via single-cell-to-bulk transcriptome mapping.

  PLoS Comput Biol, Oct 2026

• Advancing Patient-Centred AI With Adaptive Machine Learning.

  Cancer Med, Oct 2026

• Machine learning-driven M2 macrophage signature for precision prediction of survival and therapy response in acute myeloid leukemia.

  Inflamm Res, Sept 2026

• Construction and evaluation of a machine-learning-based prediction model for pneumonia in patients with acute leukemia.

  Leuk Res, Sept 2026

• Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy.

  Cancer Med, Sept 2026

• TargetPrior: a miRNA-signature embedded evolutionary learning framework for prioritizing drug targets in acute myeloid leukemia.

  Bioinformatics, Aug 2026

• Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia.

  Cells, Aug 2026

• OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

  Bioorg Med Chem Lett, Jun 2026

• Machine learning-guided risk stratification in elderly AML based on genomic, immunophenotypic and therapeutic profiles.

  BMC Geriatr, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.